afatinib + pemetrexed + gemcitabine + cisplatin + carboplatin

This combination therapy consisting of afatinib, pemetrexed, gemcitabine, cisplatin, and carboplatin is not identified as a known or studied single treatment regimen based on available search results. The search results primarily discuss various combinations of these drugs, most notably a phase I study investigating the combination of afatinib, carboplatin, and pemetrexed for EGFR-mutated non-small cell lung cancer (NSCLC) patients who progressed during treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs). Other combinations involving subsets of these drugs (e.g., afatinib with carboplatin, cisplatin plus pemetrexed, gefitinib with pemetrexed and carboplatin) have been studied, but not the specific five-drug combination requested.